Transcription factors and chromatin proteins as therapeutic targets in cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1855, Issue 2, 2015, Pages 183-192

  Johnston, Simon J ^a   Carroll, Jason S ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cancer; Drugs; Nuclear receptors; SiRNA; Small molecules; Transcription factors

Indexed keywords

ALRN 6924; ANDROGEN RECEPTOR; ANTISENSE OLIGONUCLEOTIDE; AZD 9150; CELL NUCLEUS RECEPTOR; CELL PROTEIN; CHROMATIN PROTEIN; DNA METHYLTRANSFERASE; FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN; FULVESTRANT; HEPATOCYTE NUCLEAR FACTOR 3BETA; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE METHYLTRANSFERASE; JANUS KINASE 2; PEPTIDOMIMETIC AGENT; PROTEIN BCL XL; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; RITUXIMAB; RUXOLITINIB; SMALL INTERFERING RNA; STAT3 PROTEIN; TAMOXIFEN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENETOCLAX; CHROMATIN; RNA, SMALL INTERFERING; SMALL MOLECULE LIBRARIES; TRANSCRIPTION FACTORS;

BREAST CANCER; CANCER RESEARCH; CANCER THERAPY; CHROMATIN; CHRONIC LYMPHATIC LEUKEMIA; DNA METHYLATION; DRUG MECHANISM; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTONE MODIFICATION; HODGKIN DISEASE; LARGE CELL LYMPHOMA; LIGAND BINDING; MANTLE CELL LYMPHOMA; MYELOPROLIFERATIVE NEOPLASM; ONCOGENE C MYC; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DNA INTERACTION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; RNA DEGRADATION; SOLID TUMOR; TRANSCRIPTION REGULATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; THERAPEUTIC USE;

CHROMATIN; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; TRANSCRIPTION FACTORS;

EID: 84923350702     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2015.02.002     Document Type: Review

References (128)

1. Carrera I., Treisman J.E. Message in a nucleus: signaling to the transcriptional machinery. Curr. Opin. Genet. Dev. 2008, 18(5):397-403.
2. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
3. Darnell J.E. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2002, 2(10):740-749.
4. Greenstein S., Ghias K., Krett N.L., Rosen S.T. Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin. Cancer Res. 2002, 8(6):1681-1694.
5. Rajkumar S.V. Treatment of multiple myeloma. Nat. Rev. Clin. Oncol. 2011, 8(8):479-491.
6. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
7. Koehler A.N. A complex task? Direct modulation of transcription factors with small molecules. Curr. Opin. Chem. Biol. 2010, 14(3):331-340.
8. Allred D.C., Brown P., Medina D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res. 2004, 6(6):240-245.
9. Thurlimann B., Keshaviah A., Coates A.S., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 2005, 353(26):2747-2757.
10. Cuzick J., Sestak I., Baum M., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010, 11(12):1135-1141.
11. Jordan V.C. Tamoxifen: a most unlikely pioneering medicine. Nat. Rev. Drug Discov. 2003, 2(3):205-213.
12. Johnston S.J., Cheung K.L. Fulvestrant - a novel endocrine therapy for breast cancer. Curr. Med. Chem. 2010, 17(10):902-914.
13. Santen R.J. Clinical review 37: endocrine treatment of prostate cancer. J. Clin. Endocrinol. Metab. 1992, 75(3):685-689.
14. Attard G., Richards J., De Bono J.S. New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin. Cancer Res. 2011, 17(7):1649-1657.
15. Scher H.I., Fizazi K., Saad F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 2012, 367(13):1187-1197.
16. Hegde N.S., Sanders D.A., Rodriguez R., Balasubramanian S. The transcription factor FOXM1 is a cellular target of the natural product thiostrepton. Nat. Chem. 2011, 3(9):725-731.
17. Myatt S.S., Lam E.W. The emerging roles of forkhead box (Fox) proteins in cancer. Nat. Rev. Cancer 2007, 7(11):847-859.
18. Arkin M.R., Wells J.A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 2004, 3(4):301-317.
19. Vassilev L.T., Vu B.T., Graves B., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303(5659):844-848.
20. Klein C., Vassilev L.T. Targeting the p53-MDM2 interaction to treat cancer. Br. J. Cancer 2004, 91(8):1415-1419.
21. Brown C.J., Lain S., Verma C.S., Fersht A.R., Lane D.P. Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 2009, 9(12):862-873.
22. Tovar C., Graves B., Packman K., et al. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res. 2013, 73(8):2587-2597.
23. Ray-Coquard I., Blay J.Y., Italiano A., et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 2012, 13(11):1133-1140.
24. Andreeff M., Kelly K.R., Yee K., et al. Results of the phase 1 trial of RG7112, a small-molecule MDM2 antagonist, in acute leukemia. 54th Annual Meeting of the American Society of Hematology. Georgia, Atlanta 2012.
25. Redmond A.M., Carroll J.S. Defining and targeting transcription factors in cancer. Genome Biol. 2009, 10(7):311.
26. Zhao Y., Yu S., Sun W., et al. A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice. J. Med. Chem. 2013, 56(13):5553-5561.
27. Zhao Y., Aguilar A., Bernard D., Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 inhibitors) in clinical trials for cancer treatment. J. Med. Chem. 2015, 58(3):1038-1052.
28. Zhao Y., Bernard D., Wang S. Small molecule inhibitors of MDM2-p53 and MDMX-p53 interactions as new cancer therapeutics. Biodiscovery 2013, 8(4):1-15.
29. Wade M., Li Y.C., Wahl G.M. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat. Rev. Cancer 2013, 13(2):83-96.
30. Joerger A.C., Ang H.C., Fersht A.R. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(41):15056-15061.
31. Boeckler F.M., Joerger A.C., Jaggi G., Rutherford T.J., Veprintsev D.B., Fersht A.R. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(30):10360-10365.
32. Essmann F., Schulze-Osthoff K. Translational approaches targeting the p53 pathway for anti-cancer therapy. Br. J. Pharmacol. 2012, 165(2):328-344.
33. Verdine G.L., Hilinski G.J. Stapled peptides for intracellular drug targets. Methods Enzymol. 2012, 503:3-33.
34. Walensky L.D., Kung A.L., Escher I., et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 2004, 305(5689):1466-1470.
35. Moellering R.E., Cornejo M., Davis T.N., et al. Direct inhibition of the NOTCH transcription factor complex. Nature 2009, 462(7270):182-188.
36. Bernal F., Wade M., Godes M., et al. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell 2010, 18(5):411-422.
37. Okamoto T., Zobel K., Fedorova A., et al. Stabilizing the pro-apoptotic BimBH3 helix (BimSAHB) does not necessarily enhance affinity or biological activity. ACS Chem. Biol. 2013, 8(2):297-302.
38. Lamb H.M., Hardwick J.M. Unlatched BAX pairs for death. Cell 2013, 152(3):383-384.
39. Chang Y.S., Graves B., Guerlavais V., et al. Stapled alpha-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(36):E3445-E3454.
40. Ahn J.M., Boyle N.A., Macdonald M.T., Janda K.D. Peptidomimetics and peptide backbone modifications. Mini Rev. Med. Chem. 2002, 2(5):463-473.
41. Ravindranathan P., Lee T.K., Yang L., et al. Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Nat. Commun. 2013, 4:1923.
42. Furqan M., Akinleye A., Mukhi N., Mittal V., Chen Y., Liu D. STAT inhibitors for cancer therapy. J. Hematol. Oncol. 2013, 6:90.
43. Garcia R., Yu C.L., Hudnall A., et al. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ. 1997, 8(12):1267-1276.
44. Garcia R., Bowman T.L., Niu G., et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001, 20(20):2499-2513.
45. Dechow T.N., Pedranzini L., Leitch A., et al. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(29):10602-10607.
46. Bromberg J.F., Wrzeszczynska M.H., Devgan G., et al. Stat3 as an oncogene. Cell 1999, 98(3):295-303.
47. Chen J., Bai L., Bernard D., et al. Structure-based design of conformationally constrained, cell-permeable STAT3 inhibitors. ACS Med. Chem. Lett. 2010, 1(2):85-89.
48. Geistlinger T.R., Guy R.K. Novel selective inhibitors of the interaction of individual nuclear hormone receptors with a mutually shared steroid receptor coactivator 2. J. Am. Chem. Soc. 2003, 125(23):6852-6853.
49. Tse C., Shoemaker A.R., Adickes J., et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008, 68(9):3421-3428.
50. Souers A.J., Leverson J.D., Boghaert E.R., et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 2013, 19(2):202-208.
51. Gandhi L., Camidge D.R., Ribeiro De Oliveira M., et al. Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J. Clin. Oncol. 2011, 29(7):909-916.
52. Bielinska A., Shivdasani R.A., Zhang L.Q., Nabel G.J. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science 1990, 250(4983):997-1000.
53. Morishita R., Gibbons G.H., Horiuchi M., et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc. Natl. Acad. Sci. U. S. A. 1995, 92(13):5855-5859.
54. Crinelli R., Bianchi M., Gentilini L., Magnani M. Design and characterization of decoy oligonucleotides containing locked nucleic acids. Nucleic Acids Res. 2002, 30(11):2435-2443.
55. Sen M., Thomas S.M., Kim S., et al. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov. 2012, 2(8):694-705.
56. Bochman M.L., Paeschke K., Zakian V.A. DNA secondary structures: stability and function of G-quadruplex structures. Nat. Rev. Genet. 2012, 13(11):770-780.
57. Eddy J., Maizels N. Gene function correlates with potential for G4 DNA formation in the human genome. Nucleic Acids Res. 2006, 34(14):3887-3896.
58. Verma A., Halder K., Halder R., et al. Genome-wide computational and expression analyses reveal G-quadruplex DNA motifs as conserved cis-regulatory elements in human and related species. J. Med. Chem. 2008, 51(18):5641-5649.
59. Balasubramanian S., Hurley L.H., Neidle S. Targeting G-quadruplexes in gene promoters: a novel anticancer strategy?. Nat. Rev. Drug Discov. 2011, 10(4):261-275.
60. Eddy J., Maizels N. Conserved elements with potential to form polymorphic G-quadruplex structures in the first intron of human genes. Nucleic Acids Res. 2008, 36(4):1321-1333.
61. Todd A.K., Neidle S. The relationship of potential G-quadruplex sequences in cis-upstream regions of the human genome to SP1-binding elements. Nucleic Acids Res. 2008, 36(8):2700-2704.
62. Nesbit C.E., Tersak J.M., Prochownik E.V. MYC oncogenes and human neoplastic disease. Oncogene 1999, 18(19):3004-3016.
63. Meyer N., Penn L.Z. Reflecting on 25years with MYC. Nat. Rev. Cancer 2008, 8(12):976-990.
64. Dang C.V. MYC on the path to cancer. Cell 2012, 149(1):22-35.
65. Siddiqui-Jain A., Grand C.L., Bearss D.J., Hurley L.H. Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(18):11593-11598.
66. Sun D., Hurley L.H. The importance of negative superhelicity in inducing the formation of G-quadruplex and i-motif structures in the c-Myc promoter: implications for drug targeting and control of gene expression. J. Med. Chem. 2009, 52(9):2863-2874.
67. Welsh S.J., Dale A.G., Lombardo C.M., et al. Inhibition of the hypoxia-inducible factor pathway by a G-quadruplex binding small molecule. Sci. Rep. 2013, 3:2799.
68. Sun H., Xiang J., Shi Y., et al. A newly identified G-quadruplex as a potential target regulating Bcl-2 expression. Biochim. Biophys. Acta 2014, 1840(10):3052-3057.
69. Rand T.A., Ginalski K., Grishin N.V., Wang X. Biochemical identification of Argonaute 2 as the sole protein required for RNA-induced silencing complex activity. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(40):14385-14389.
70. Matranga C., Tomari Y., Shin C., Bartel D.P., Zamore P.D. Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 2005, 123(4):607-620.
71. Deng Y., Wang C.C., Choy K.W., et al. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene 2014, 538(2):217-227.
72. Tabernero J., Shapiro G.I., Lorusso P.M., et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013, 3(4):406-417.
73. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 2009, 8(2):129-138.
74. Rao D.D., Vorhies J.S., Senzer N., Nemunaitis J. siRNA vs. shRNA: similarities and differences. Adv. Drug Deliv. Rev. 2009, 61(9):746-759.
75. Hsu P.D., Lander E.S., Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014, 157(6):1262-1278.
76. Dias N., Stein C.A. Antisense oligonucleotides: basic concepts and mechanisms. Mol. Cancer Ther. 2002, 1(5):347-355.
77. Hong D.S., Younes A., Fayad L., et al. A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers. J. Clin. Oncol. 2013, 31. (supplement, abstract 8523).
78. NCT01563302 Phase 1/2, open-label, dose-escalation study of ISIS-STAT3Rx, administered to patients with advanced cancers http://ClinicalTrials.gov.
79. Filtz T.M., Vogel W.K., Leid M. Regulation of transcription factor activity by interconnected post-translational modifications. Trends Pharmacol. Sci. 2014, 35(2):76-85.
80. Ciruelos Gil E.M. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat. Rev. 2014, 40(7):862-871.
81. Shuai K., Liu B. Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. 2003, 3(11):900-911.
82. Fridman J.S., Scherle P.A., Collins R., et al. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J. Investig. Dermatol. 2011, 131(9):1838-1844.
83. Wolfrum C., Besser D., Luca E., Stoffel M. Insulin regulates the activity of forkhead transcription factor Hnf-3beta/Foxa-2 by Akt-mediated phosphorylation and nuclear/cytosolic localization. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(20):11624-11629.
84. Carroll J.S., Liu X.S., Brodsky A.S., et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005, 122(1):33-43.
85. Hurtado A., Holmes K.A., Ross-Innes C.S., Schmidt D., Carroll J.S. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat. Genet. 2011, 43(1):27-33.
86. Imamura Y., Sakamoto S., Endo T., et al. FOXA1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway. PLoS One 2012, 7(8):e42456.
87. Zhang C., Wang L., Wu D., et al. Definition of a FoxA1 cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. Cancer Res. 2011, 71(21):6738-6748.
88. Tarakhovsky A. Tools and landscapes of epigenetics. Nat. Immunol. 2010, 11(7):565-568.
89. Gallenkamp D., Gelato K.A., Haendler B., Weinmann H. Bromodomains and their pharmacological inhibitors. ChemMedChem 2014, 9(3):438-464.
90. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 2011, 11(10):726-734.
91. Jones P.A., Liang G. Rethinking how DNA methylation patterns are maintained. Nat. Rev. Genet. 2009, 10(11):805-811.
92. Quintas-Cardama A., Santos F.P., Garcia-Manero G. Therapy with azanucleosides for myelodysplastic syndromes. Nat. Rev. Clin. Oncol. 2010, 7(8):433-444.
93. Wilson V.L., Jones P.A., Momparler R.L. Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2'-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res. 1983, 43(8):3493-3496.
94. Momparler R.L., Bouchard J., Onetto N., Rivard G.E. 5-aza-2'-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation. Leuk. Res. 1984, 8(2):181-185.
95. Von Hoff D.D., Slavik M. 5-azacytidine-a new anticancer drug with significant activity in acute myeloblastic leukemia. Adv. Pharmacol. Chemother. 1977, 14:285-326.
96. Tsai H.C., Li H., Van Neste L., et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012, 21(3):430-446.
97. Silverman L.R., Demakos E.P., Peterson B.L., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 2002, 20(10):2429-2440.
98. Fenaux P., Ades L. Review of azacitidine trials in Intermediate-2-and high-risk myelodysplastic syndromes. Leuk. Res. 2009, 33(Suppl. 2):S7-S11.
99. Kornblith A.B., Herndon J.E., Silverman L.R., et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J. Clin. Oncol. 2002, 20(10):2441-2452.
100. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5(9):769-784.
101. O'connor O.A., Heaney M.L., Schwartz L., et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. 2006, 24(1):166-173.
102. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6(1):38-51.
103. Whittaker S.J., Demierre M.F., Kim E.J., et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 2010, 28(29):4485-4491.
104. Olsen E.A., Kim Y.H., Kuzel T.M., et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 2007, 25(21):3109-3115.
105. Dickinson M., Johnstone R.W., Prince H.M. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Investig. New Drugs 2010, 28(Suppl. 1):S3-S20.
106. Rahmani M., Reese E., Dai Y., et al. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Mol. Pharmacol. 2005, 67(4):1166-1176.
107. Zuber J., Shi J., Wang E., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478(7370):524-528.
108. Dawson M.A., Prinjha R.K., Dittmann A., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011, 478(7370):529-533.
109. Lin C., Smith E.R., Takahashi H., et al. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol. Cell 2010, 37(3):429-437.
110. Mertz J.A., Conery A.R., Bryant B.M., et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(40):16669-16674.
111. Daigle S.R., Olhava E.J., Therkelsen C.A., et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 2013, 122(6):1017-1025.
112. Mccabe M.T., Ott H.M., Ganji G., et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012, 492(7427):108-112.
113. Varambally S., Cao Q., Mani R.S., et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008, 322(5908):1695-1699.
114. Knutson S.K., Kawano S., Minoshima Y., et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol. Cancer Ther. 2014, 13(4):842-854.
115. Kim W., Bird G.H., Neff T., et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat. Chem. Biol. 2013, 9(10):643-650.
116. Sareddy G.R., Nair B.C., Krishnan S.K., et al. KDM1 is a novel therapeutic target for the treatment of gliomas. Oncotarget 2013, 4(1):18-28.
117. Ueda R., Suzuki T., Mino K., et al. Identification of cell-active lysine specific demethylase 1-selective inhibitors. J. Am. Chem. Soc. 2009, 131(48):17536-17537.
118. Cortez V., Mann M., Tekmal S., et al. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res. 2012, 14(4):R108.
119. Balakrishnan A., Bleeker F.E., Lamba S., et al. Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res. 2007, 67(8):3545-3550.
120. Muraoka M., Konishi M., Kikuchi-Yanoshita R., et al. p300 gene alterations in colorectal and gastric carcinomas. Oncogene 1996, 12(7):1565-1569.
121. Van Haaften G., Dalgliesh G.L., Davies H., et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 2009, 41(5):521-523.
122. Toy W., Shen Y., Won H., et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 2013, 45(12):1439-1445.
123. Robinson D.R., Wu Y.M., Vats P., et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 2013, 45(12):1446-1451.
124. Merenbakh-Lamin K., Ben-Baruch N., Yeheskel A., et al. D538G mutation in estrogen receptor-alpha: a novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res. 2013, 73(23):6856-6864.
125. Moras D., Gronemeyer H. The nuclear receptor ligand-binding domain: structure and function. Curr. Opin. Cell Biol. 1998, 10(3):384-391.
126. Huang P., Chandra V., Rastinejad F. Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Annu. Rev. Physiol. 2010, 72:247-272.
127. Tritton T.R., Hickman J.A. How to kill cancer cells: membranes and cell signaling as targets in cancer chemotherapy. Cancer Cells 1990, 2(4):95-105.
128. Powis G. Signalling targets for anticancer drug development. Trends Pharmacol. Sci. 1991, 12(5):188-194.